Savara, Inc. (SVRA)

[lux1]

I started to read articles about Savara drugs, imo, Molgradex would be well positioned for an easy and very fast approval in UE and Japan. In some clinical tests results was excellent (that's a reason Savara bought the company Serendex and its drugs).
Although the market for Molgradex is small, have an orphan drug approved is disruptive for a small bio company and the results of the P2/3 are expected in Q1/2018.
I'll follow Savara at least until these results.